GSK Loses Bid For Avodart Prostate Cancer Prevention Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's "complete response" letter would appear to dampen the company's most lucrative opportunity for expanding the benign prostatic hyperplasia drug's indication before entry of generic competition.